Introduction: We present clinical outcomes after SSM in operable breast cancer especially in light of increased diagnoses of in situ disease after screening and increased usage of adjuvant aromatase inhibitors (AIs) in recent years.
Patients And Methods: Case records of 81 patients who had SSM for cancer over 4 years (April 2006-July 2010) were reviewed.
Results: Eighty-one patients (median age, 51.